Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review
- 1 October 2000
- journal article
- review article
- Published by Elsevier in Clinical Therapeutics
- Vol. 22 (10) , 1151-1168
- https://doi.org/10.1016/s0149-2918(00)83060-x
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Effect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes MellitusJAMA, 2000
- Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazoneBritish Journal of Clinical Pharmacology, 1999
- Pharmacokinetics of rosiglitazone are unaltered in hemodialysis patientsClinical Pharmacology & Therapeutics, 1999
- Effect of renal impairment on the pharmacokinetics of rosiglitazone (RSG)Clinical Pharmacology & Therapeutics, 1999
- Effect of hepatic impairment on the pharmacokinetics (PK) of rosiglitazone (RSG)Clinical Pharmacology & Therapeutics, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- The Short- and Long-Term Effects of Tumor Necrosis Factor- and BRL 49653 on Peroxisome Proliferator-Activated Receptor (PPAR) 2 Gene Expression and Other Adipocyte GenesMolecular Endocrinology, 1998
- Consensus Development Conference on Insulin Resistance: 5–6 November 1997Diabetes Care, 1998
- Thiazolidinediones in the treatment of insulin resistance and type II diabetesDiabetes, 1996
- An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)Journal of Biological Chemistry, 1995